Fifth Dimension    Catalog    Contact Us
graphic to create line
Cancer Supportive and Survivorship Care Improving Quality of Life Logo

References for Chemotherapy-induced Peripheral Neuropathy Fact Sheet
Meredith A. Wampler, PT, DPTSc and Ernest H. Rosenbaum, MD

References Chemotherapy-induced Peripheral Neuropathy Fact Sheet

1. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. Mar 1994;35(3):304-311.
2. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. Oct 1997;35(1):47-53.
3. Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs. Apr 2005;9(2):189-193.
4. Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. Jan 28 2003;60(2):337-340.
5. Taxol Prescribing Information. Accessed April 13, 2005.
6. Taxotere Prescribing Information. Accessed April 13, 2005.
7. Abraxane Prescribing Information. Accessed April 13, 2005.
8. Prescribing Information for Navelbine. Accessed April 13, 2005.

9. Prescribing Information Vincristine. Accessed April 13, 2005.
10. Carboplatin Presribing Information. Accessed April 13, 2005.
11. Oxaliplatin Prescribing Information. Accessed April 13, 2005.
12. Cisplatin Prescribing Information. Accessed April 13, 2005.
13. Wampler MA, Hamel, K., Topp, K. S. Impairments in postural control resulting from taxane-induced peripheral neuropathy in women with breast cancer. Paper presented at: International Society of Posture and Gait Research Annual Meeting, 2005; Marseilles, France.
14. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. May 2004;109(1-2):132-142.
15. Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol. Jun 15 2004;22(12):2461-2468.
16. Wampler MA, Rugo, H., Rosenbaum, E., Miaskowski, C. Evaluation and Treatment Recommendations for Taxane-Induced Peripheral Neuropathy in Women with Breast Cancer. Paper presented at: Supportive Oncology Conference, 2005; Chicago, IL.

17. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. Nov 1994;17(11):1281-1289.
18. Bloom S, Till S, Sonksen P, Smith S. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. Br Med J (Clin Res Ed). Jun 16 1984;288(6433):1793-1795.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. Jan 1 1981;47(1):207-214.
20. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. Feb 1997;48(2):332-338.
21. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer. Aug 15 2003;98(4):822-831.
22. Richardson JK, Sandman D, Vela S. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil. Feb 2001;82(2):205-209.
23. Galer BS, Dworkin, R.H. A clinical guide to neuropathic pain: The McGraw Hill Companies; 2000.

You are welcome to share this © article with friends, but do not forget to include the author name and web address. Permission needed to use articles on commercial and non commercial websites. Thank you.